Combination chemotherapy with TAS‑102 plus bevacizumab in salvage‑line treatment of metastatic colorectal cancer: A single‑center, retrospective study examining the prognostic value of the modified Glasgow Prognostic Score in salvage‑line therapy of metastatic colorectal cancer-Reference-Cited by-同舟云学术

Combination chemotherapy with TAS‑102 plus bevacizumab in salvage‑line treatment of metastatic colorectal cancer: A single‑center, retrospective study examining the prognostic value of the modified Glasgow Prognostic Score in salvage‑line therapy of metastatic colorectal cancer

Published:2019-07-18 Issue: Volume: Page:
ISSN:2049-9450
Container-title:Molecular and Clinical Oncology
language:
Short-container-title:mol clin onc

Author:

Matsuhashi Nobuhisa¹,Takahashi Takao¹,Fujii Hironori²,Suetsugu Tomonari¹,Fukada Masahiro¹,Iwata Yoshinori¹,Tokumaru Yoshihisa¹,Imai Takeharu¹,Mori Ryutaro¹,Tanahashi Toshiyuki¹,Matsui Satoshi¹,Imai Hisashi¹,Tanaka Yoshihiro¹,Yamaguch Kazuya¹,Futamura Manabu¹,Yoshida Kazuhiro¹

Affiliation:

1. Department of Surgical Oncology, Gifu University School of Medicine, Gifu 501‑1194, Japan

2. Department of Pharmacy, Gifu University Hospital, Gifu 501‑1194, Japan

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110);ESMO Open;2024-05

2. Efficacy and Safety of Trifluridine/Tipiracil-Containing Combinations in Colorectal Cancer and Other Advanced Solid Tumors: A Systematic Review;The Oncologist;2024-02-16

3. A Systematic Review and Meta-Analysis of Trifluridine/Tipiracil plus Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Evidence from Real-World Series;Current Oncology;2023-05-24

4. Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study);International Journal of Clinical Oncology;2022-10-06

5. Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting;Scientific Reports;2022-08-26